Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R (2024) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, et al. Journal article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE) (2022) Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, et al. Journal article Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry (2022) Laakmann E, Witzel I, Neunhoeffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, et al. Journal article Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) Müller V, Banys-Paluchowski M, Friedl TW, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, et al. Journal article Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy (2021) Hassel JC, Livingstone E, Allam JP, Behre HM, Bojunga J, Klein HH, Landsberg J, et al. Journal article, Review article Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials (2020) Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H, Gaipl U Journal article, Review article Tolerability of BRAF/MEK inhibitor combinations: Adverse event evaluation and management (2019) Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, et al. Journal article, Review article